Together for Short Lives
Call the Helpline 0808 8088 100

The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis

Journal title
Drug safety
Publication year
2016
Author(s)
Lau Moon Lin, M.; Robinson, P. D.; Flank, J.; Sung, L.; Dupuis, L. L.

INTRODUCTION: Metoclopramide is recommended for adults with breakthrough or refractory chemotherapy-induced nausea and vomiting (CINV) and for CINV prophylaxis in children. The drug regulatory agencies of Canada and the EU have revised the labelling of metoclopramide to contraindicate its use in children aged <1 year and to caution against its use in children aged <5 years and its duration of use beyond 5 days. OBJECTIVE: This review describes the safety of metoclopramide in children when given for any indication. METHODS: We conducted electronic searches in MEDLINE and Embase as of 9 March 2015. All studies in English reporting adverse effects associated with the use of metoclopramide in children (aged

Research abstracts